Christopher Wick is Relief Therapeutics’ U.S. Country Lead and is responsible for leading company’s U.S. commercial and sales teams. He joined Relief in March 2022 as the head of the U.S. sales team.
Prior to joining Relief, Mr. Wick served as a regional sales director at Alexion Pharmaceuticals, Inc., where he developed and led two high-performing, Excellence Award-winning teams which achieved best in the nation sales for two product launches of Soliris®, for the treatment of neuromyelitis optica spectrum disorder (NOSD) and generalized myasthenia gravis (gMG). Between 2015 to 2018, Mr. Wick served as Alexion's southwest regional account manager, where he cultivated a regional key opinion leader physician network while launching two of Alexion's enzyme replacement therapies for ultra-rare disease.
Mr. Wick also served in positions of increasing responsibility at GlaxoSmithKline from 2007 until 2015. Most recently, he was the southwest health systems account manager where he worked to ensure early adoption of GSK's launch products as well as the entire pharmaceutical and biologic portfolio. In that role, Mr. Wick was responsible for hospital system contracts, and collaborating with GSK's largest and most complex accounts in the integrated delivery networks (IDN) and hospital customer segment.
Prior to that, Mr. Wick was an executive account manager at Novartis. While there, he contributed to both specialty and hospital sales, served as a national training leader and regional trainer and consistently achieved a top 15% sales ranking.
Mr. Wick attended Purdue University in West Lafaytte, Ind. and earned a bachelor of arts degree in business administration from New Mexico State University in Las Cruses, N.M.